Ketamine for depression: all studies (page 35)

Blunted arginine vasopressin secretion in individuals experiencing a major depressive episode with comorbid post-traumatic stress disorder: Results from an exploratory study using copeptin as a surrogate marker.

Journal of Neuroendocrinology 2026 Hiroe Hu, Yoojin Lee, Alaina N Tillman et al. 1 citation

Arginine vasopressin (AVP) modulates stress responsivity and social-affective behaviors, but its role in mood and trauma-related disorders remains poorly defined due to challenges in peripheral measurement. This study used copeptin, a stable, reliable, and well-validated surrogate marker of AVP secretion, to assess vasopressinergic function in a transdiagnostic sample of individuals...

DOI: 10.1111/jne.70133 Full text PTSD Depression Ketamine Copeptin +1

DXM, CYP2D6-inhibiting antidepressants, piracetam, and glutamine: proposing a ketamine-class antidepressant regimen with existing drugs.

Frontiers in Psychiatry 2026 Ngo Cheung 6 citations

Rapid-acting antidepressants show that mood can lift within hours when glutamatergic circuits shift from an "NMDA-dominant" to an "AMPA-dominant" state. Intravenous ketamine achieves this flip but is hampered by dissociation and logistics, while dextromethorphan + bupropion (Auvelity®) primarily supplies the initial NMDA blockade and yields slower, less durable benefit. We hypothesize that a...

DOI: 10.3389/fpsyt.2026.1751605 Full text Depression Ketamine Cyp2d6-inhibiting antidepressants Dxm +3

Modulation of Magnetic Resonance Spectroscopy Levels of Glutamate and GABA by Ketamine in Treatment-Resistant Depression.

Journal of Neuroscience Research 2026 Stephanie N Njau, Artemis Zavaliangos-Petropulu, Shantanu Joshi et al.

Ketamine has emerged as a highly effective intervention for treatment-resistant depression (TRD). Though it acts as a non-competitive antagonist of excitatory N-methyl-D-aspartate receptors (NMDAR), widely expressed in the brain, including on inhibitory γ-aminobutyric acid (GABA)-ergic cells, the mechanisms of its antidepressant action are less clear. To investigate the links between glutamate...

DOI: 10.1002/jnr.70102 Full text Depression Ketamine

Ketamine combined with psychotherapy for treatment-resistant depression: Real-world outcomes and the role of subjective experience.

General Hospital Psychiatry 2026 Rebeca Cohen, João Bastos, Catarina Cunha et al. 1 citation

Ketamine, an N-methyl-d-aspartate antagonist, shows promise for treatment-resistant depression (TRD), with psychedelic doses potentially enhancing efficacy. However, its transient antidepressant effects and the need for repeated infusions raise concerns about optimal duration and long-term safety. Two clinical trials have tested the combination of ketamine with psychotherapy for depression,...

DOI: 10.1016/j.genhosppsych.2026.02.001 Full text Ego dissolution Ketamine Treatment-resistant depression Antidepressant +1

Mental health professionals' perspective on the use of esketamine in treatment-resistant depression and their motivation to adopt it: a Saudi cross-sectional study.

Frontiers in Psychiatry 2026 Ahmad H Almadani, Ayedh H Alghamdi, Gosay M Almazyad et al.

Esketamine is an innovative treatment for individuals with treatment-resistant depression (TRD). However, its adoption could depend on the perceptions and motivations of prescribing psychiatrists, among other factors. This study aims to explore the attitudes of psychiatrists (of all levels, including those in training) across Saudi Arabia toward the use of esketamine for TRD and investigate the...

DOI: 10.3389/fpsyt.2026.1726411 Full text Esketamine Treatment-resistant depression Saudi arabia Attitudes +1

Single low-dose esketamine improves postpartum depression symptoms and recovery quality in cesarean section women.

American Journal of Translational Research 2026 Ran Jing, Yuanyan Tu

To investigate the effects of single low-dose esketamine combined with patient-controlled intravenous analgesia (PCIA) on early postpartum depression symptoms and recovery quality in women undergoing cesarean section. This prospective, randomized, controlled study enrolled 136 women scheduled for elective cesarean section, who were randomly assigned in a 1:1 ratio to the study group (esketamine...

DOI: 10.62347/euok7911 Full text Esketamine Low dose Cesarean section Patient-controlled intravenous analgesia +1

Evaluating the potential risk of ketamine-induced hepatotoxicity in the treatment of mood and anxiety disorders: A systematic review.

General Hospital Psychiatry 2026 Gabrielle F. M. Lovell, Shreya Vasudeva, Diana Orsini et al.

Ketamine is a dissociative anesthetic with potential for treating mood, anxiety, and related disorders; however, concerns have emerged regarding hepatotoxicity in the context of chronic treatment. Systematic searches of PubMed, Scopus, and Ovid databases were conducted from inception to August 2025. Eligible studies included randomized controlled trials (RCTs), observational studies, and case...

DOI: 10.1016/j.genhosppsych.2026.04.005 Full text Esketamine Major depressive disorder Alanine aminotransferase Aspartate aminotransferase +2

Esketamine ameliorates depression-like behavior in mice via modulation of the NRG1-ErbB4 pathway.

Frontiers in Psychiatry 2026 Hang Yu, Yuqiong Zhu, Jie Wang et al.

Esketamine has a significant and rapid antidepressant effect. Although studies have shown that Neuregulin 1 (NRG1) and it's signaling pathway are associated with depression, the possible regulatory relationship of esketamine on the NRG1-ErbB4 pathway is not yet clear. To induce depressive-like behavior in mice, a Chronic Social Defeat Stress (CSDS) model was established. Behavioral indicators...

DOI: 10.3389/fpsyt.2026.1722336 Full text Esketamine Erbb4 Nrg1 Depression disorder

Intranasal esketamine in treatment-resistant depression: long-term dosing patterns and clinical outcomes in a 5-year observational study.

Therapeutic Advances in Psychopharmacology 2026 Alessandro Cuomo, Roger S McIntyre, Despoina Koukouna et al. 1 citation

Treatment-resistant depression (TRD) remains a major clinical challenge, and long-term real-world data on intranasal esketamine are limited. To describe long-term dosing patterns and clinical outcomes associated with intranasal esketamine in routine clinical practice. Single-center observational cohort study with descriptive analyses. We analyzed 45 patients with TRD treated with intranasal...

DOI: 10.1177/20451253261437597 Full text Esketamine Treatment-resistant depression Madrs Dosing patterns +6

Rapid reduction of suicidal ideation with transient dissociative and "drunken gait" symptoms after intranasal esketamine, with music intervention: a case report.

Frontiers in Psychiatry 2026 Haihua Tian, Zongfeng Zhang, Yan He et al. 1 citation

Treatment-resistant depression (TRD) is often accompanied by persistent suicidal ideation and poor response to conventional antidepressants. Intranasal esketamine, a non-selective NMDA receptor antagonist, provides rapid antidepressant and anti-suicidal effects; transient dissociation is common, whereas ataxia-like "drunken gait" is rarely described. A 19-year-old woman with recurrent...

DOI: 10.3389/fpsyt.2026.1739904 Full text Esketamine Treatment-resistant depression Dissociative symptoms Drunken gait +2